Hemay Pharmaceutical Announces Hong Kong IPO of up to 55.21 Million H Shares at HK$15.50–18.90 Each

Bulletin Express10-30

Ganzhou Hemay Pharmaceutical Co., Ltd. (Hemay Pharmaceutical) has launched its Global Offering on the Hong Kong Stock Exchange, aiming to list its H shares under the stock code 0054.

The company is offering 55.21 million H shares with a nominal value of RMB1.00 each. The offer price is capped at HK$18.90 per share and will not be set below HK$15.50, unless the issuer exercises a Downward Offer Price Adjustment of up to 10%, which would reduce the floor to HK$14.00.

Offer Structure • Hong Kong Public Offering: 5.52 million H shares, representing approximately 10% of the total offer (subject to reallocation). • International Offering: 49.69 million H shares, representing approximately 90% of the total offer (subject to reallocation and an over-allotment option).

Pricing and Allocation • Applications under the Hong Kong Public Offering require payment based on the maximum offer price of HK$18.90 per share, plus applicable levies and fees. • Final pricing will be determined no later than November 5, 2026 (Hong Kong time). • If a downward adjustment is made, the company will publish a separate announcement by November 6, 2026.

Timetable Highlights (Hong Kong Time) • Offer period: 9:00 a.m. on October 30, 2026 to 12:00 noon on November 4, 2026. • Price Determination Date: on or before 12:00 noon, November 5, 2026. • Final offer statistics announcement: expected by 11:00 p.m., November 6, 2026. • Commencement of trading: 9:00 a.m., November 9, 2026.

Application Channels • HK eIPO White Form (www.hkeipo.hk) for investors requesting physical share certificates. • HKSCC EIPO channel via brokers or custodians for electronic applications with shares deposited directly into CCASS.

Settlement and Trading Subject to listing approval and completion of admission requirements, the H shares will be accepted for clearing and settlement in CCASS from the first day of trading. Shares will trade in board lots of 100.

Underwriting and Termination The Sole Sponsor-Overall Coordinator may terminate the Hong Kong underwriting agreement prior to 8:00 a.m. on the first trading day if specified termination events occur.

Hemay Pharmaceutical’s prospectus, application details, and the full timetable are available on the Stock Exchange website (www.hkexnews.hk) and the company website (www.hemay.com.cn).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment